navitoclax
abbvie
['melsm', 'melanoma', 'navitoclax']
unfortunately no added major efficacy adding navitoclax to braf/meki in advanced melanoma, even though formally meeting the primary endpoint cr 20% compared to historical controls. #asco23 #melsm 
Professor in Cancer Surgery at Sahlgrenska University Hospital. @sahlgrenska @SahlgrenskaAcad @goteborgUni #wcmtm #melanoma #breastcancer #surgery